Aradigm Corp. operates as a pharmaceutical company, which focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. Its technologies include diabetes and pain management, AERx essence devices. The company was founded in 1991 and is headquartered in Hayward, CA.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARDM
CUSIPN/A
Phone510-265-9000
Debt
Debt-to-Equity Ratio-1.04
Current Ratio1.22
Quick Ratio1.22
Price-To-Earnings
Trailing P/E Ratio-1.71
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$14.47 million
Price / Sales1.29
Cash FlowN/A
Price / CashN/A
Book Value($0.83) per share
Price / Book-1.48
Profitability
EPS (Most Recent Fiscal Year)($0.72)
Net Income$-10,700,000.00
Net Margins-244.15%
Return on EquityN/A
Return on Assets-240.23%
Miscellaneous
Employees23
Outstanding Shares15,200,000
Market Cap$18.39 million
Aradigm (NASDAQ:ARDM) Frequently Asked Questions
What is Aradigm's stock symbol?
Aradigm trades on the NASDAQ under the ticker symbol "ARDM."
How were Aradigm's earnings last quarter?
Aradigm Co. (NASDAQ:ARDM) released its earnings results on Tuesday, August, 14th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.03. The company had revenue of $0.26 million for the quarter. View Aradigm's Earnings History.
When is Aradigm's next earnings date?
What price target have analysts set for ARDM?
1 brokerages have issued 12-month price objectives for Aradigm's shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Aradigm's share price to reach $10.00 in the next year. This suggests a possible upside of 713.0% from the stock's current price. View Analyst Price Targets for Aradigm.
What is the consensus analysts' recommendation for Aradigm?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aradigm in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aradigm.
Who are some of Aradigm's key competitors?
Some companies that are related to Aradigm include IRIDEX (IRIX), BioSig Technologies (BSGM), Stereotaxis (STXS), Soleno Therapeutics (SLNO), Digirad (DRAD), Dynatronics (DYNT), Nexeon Medsystems (NXNND), Nexeon Medsystems (NXNN), Precision Optics (PEYE), ENDRA Life Sciences (NDRA), CHF Solutions (CHFS), Fc Global Realty (FCRE), Vaso (VASO), Non-Invasive Monitoring Systems (NIMU) and Escalon Medical (ESMC).
Who are Aradigm's key executives?
Aradigm's management team includes the folowing people:
- John M. Siebert, Executive Chairman, Chief Executive Officer & CFO
- Lisa Thomas, Controller
Has Aradigm been receiving favorable news coverage?
Headlines about ARDM stock have trended somewhat positive this week, according to Accern. The research group rates the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Aradigm earned a news and rumor sentiment score of 0.18 on Accern's scale. They also assigned news stories about the company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Aradigm.
How do I buy shares of Aradigm?
Shares of ARDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aradigm's stock price today?
One share of ARDM stock can currently be purchased for approximately $1.23.
How big of a company is Aradigm?
Aradigm has a market capitalization of $18.39 million and generates $14.47 million in revenue each year. The company earns $-10,700,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Aradigm employs 23 workers across the globe.
How can I contact Aradigm?
Aradigm's mailing address is 3929 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-265-9000 or via email at [email protected]
MarketBeat Community Rating for Aradigm (NASDAQ ARDM)
MarketBeat's community ratings are surveys of what our community members think about Aradigm and other stocks. Vote "Outperform" if you believe ARDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
